2007, Issue 4 (first review version): We removed the requirement for all participants to fulfil the World Health Organization's definition for severe malaria (Gilles 2000) in view of the large number of participants this would have excluded from the review as the largest included trial used a clinical case definition. We changed the intervention from "parenteral quinine" to "intravenous, intramuscular, or rectal artesunate" to clarify that trials using artesunate suppositories were included in the review. We changed "neurological sequelae" to "neurological sequelae at discharge" to clarify the follow‐up period for this outcome. We added the exploration of a number of post‐hoc sources of heterogeneity for mortality after noting significant variation in study design across trials. We presented data for hypoglycaemia in a forest plot rather than a table as stated in the protocol to reflect the clinical importance of this outcome.